Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02671461 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
A Phase 2 study of Thrombosis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 20
- Study locations
NCT02671461: Completed Phase 2 study of Thrombosis, sponsored by Bristol-Myers Squibb.
NCT02671461 is a Phase 2 study of Thrombosis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 16 participants, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02671461, a Phase 2 study of Thrombosis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are receiving acetylsalicylic acid (also known as aspirin or ASA) to treat the stroke or TIA.
Primary Outcome
The incidence of a composite of symptomatic ischemic stroke by Day 28 and unrecognized brain infarction assessed by MRI at Day 28 was to be reported by arm in all treated participants.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Aspirin
- DRUG BMS-986141
Study Locations (20)
Florida
- University Of Florida - Gainesville
- University Of Florida Hsc/Jacksonville - Jacksonville
- Florida Hospital - Orlando
- Intercoastal Medical Group - Sarasota
North Carolina
- Local Institution - Chapel Hill
- Duke University Medical Center - Durham
- Guilford Medical Associates, Pa - Greensboro
Massachusetts
- Tufts Medical Center - Boston
- Boston Medical Center - Boston
Arizona
- Banner University Medical Ctr - Phoenix
California
- Hoag Memorial Hospital - Newport Beach
Delaware
- Local Institution - Newark
Illinois
- Presence Saint Joseph Medical Center - Joliet
Kentucky
- University Of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-04-25 |
| Est. Completion | 2017-03-31 |
| Phase | Phase 2 |
What the finished NCT02671461 record still lists
NCT02671461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02671461 names 20 study sites across 14 states, led by Florida, North Carolina, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02671461 about?
NCT02671461 is a clinical study titled "Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"". The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are receiving acetylsalicylic acid (also known as aspirin or ASA) to treat the stro...
What is the current status of trial NCT02671461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2016-04-25. Estimated completion is 2017-03-31.
What conditions does trial NCT02671461 study?
This clinical trial studies the following conditions: Thrombosis.
What interventions are being tested in trial NCT02671461?
The interventions under investigation include: Placebo (OTHER), Aspirin (DRUG), BMS-986141 (DRUG).
Who is sponsoring clinical trial NCT02671461?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02671461 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02671461's enrollment target sits among peer trials
16 23rd of 28 higher than 5 of 28 other Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
COMPLETED · Phase 2
-
Study Of Angiomax In Infants Under Six Months With Thrombosis
COMPLETED · Phase 2
-
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
COMPLETED · Phase 2
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI